{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:17:29Z","timestamp":1790371049686,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":117,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/82_2025_336","type":"book-chapter","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:12:09Z","timestamp":1764666729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Chronic Active Epstein-Barr Virus Disease"],"prefix":"10.1007","author":[{"given":"Claire","family":"Shannon-Lowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"7","key":"336_CR1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R et al (2022) The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"issue":"47","key":"336_CR2","doi-asserted-by":"crossref","first-page":"76793","DOI":"10.18632\/oncotarget.12529","volume":"7","author":"S Ando","year":"2016","unstructured":"Ando S et al (2016) Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Oncotarget 7(47):76793\u201376805","journal-title":"Oncotarget"},{"issue":"4","key":"336_CR3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/25785826.2018.1556030","volume":"41","author":"A Arai","year":"2018","unstructured":"Arai A (2018) Chronic active Epstein-Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements. Immunol Med 41(4):162\u2013169","journal-title":"Immunol Med"},{"key":"336_CR4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fimmu.2019.00146","volume":"10","author":"MHM Barros","year":"2019","unstructured":"Barros MHM et al (2019) Revisiting the tissue microenvironment of infectious mononucleosis: identification of EBV infection in T cells and deep characterization of immune profiles. Front Immunol 10:146","journal-title":"Front Immunol"},{"issue":"1","key":"336_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.virol.2010.03.014","volume":"402","author":"GL Bentz","year":"2010","unstructured":"Bentz GL et al (2010) Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta. Virology 402(1):121\u2013128","journal-title":"Virology"},{"issue":"25","key":"336_CR6","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E et al (2017) Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130(25):2728\u20132738","journal-title":"Blood"},{"issue":"2","key":"336_CR7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/pbc.22037","volume":"53","author":"K Beutel","year":"2009","unstructured":"Beutel K et al (2009) Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer 53(2):184\u2013190","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"336_CR8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi XW et al (2016) PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol Oncol 9(1):109","journal-title":"J Hematol Oncol"},{"issue":"4","key":"336_CR9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00432-020-03139-4","volume":"146","author":"S Birndt","year":"2020","unstructured":"Birndt S et al (2020) Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol 146(4):1065\u20131077","journal-title":"J Cancer Res Clin Oncol"},{"issue":"26","key":"336_CR10","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2018-03-785931","volume":"131","author":"CM Bollard","year":"2018","unstructured":"Bollard CM, Cohen JI (2018) How I treat T-cell chronic active Epstein-Barr virus disease. Blood 131(26):2899\u20132905","journal-title":"Blood"},{"issue":"2\u20133","key":"336_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000072463","volume":"110","author":"CM Bollard","year":"2003","unstructured":"Bollard CM et al (2003) Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 110(2\u20133):139\u2013148","journal-title":"Acta Haematol"},{"issue":"8","key":"336_CR12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM et al (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32(8):798\u2013808","journal-title":"J Clin Oncol"},{"issue":"9","key":"336_CR13","volume":"44","author":"HM Cai","year":"2025","unstructured":"Cai HM et al (2025) DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis. Cell Rep 44(9):116237","journal-title":"Cell Rep"},{"issue":"11","key":"336_CR14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140(11):1229\u20131253","journal-title":"Blood"},{"issue":"3","key":"336_CR15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ejh.14029","volume":"111","author":"JEG Charlesworth","year":"2023","unstructured":"Charlesworth JEG, Kavirayani A (2023) Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review. Eur J Haematol 111(3):458\u2013476","journal-title":"Eur J Haematol"},{"issue":"2","key":"336_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1385\/IR:34:2:117","volume":"34","author":"M Ciofani","year":"2006","unstructured":"Ciofani M, Zuniga-Pflucker JC (2006) A survival guide to early T cell development. Immunol Res 34(2):117\u2013132","journal-title":"Immunol Res"},{"issue":"22","key":"336_CR17","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/blood-2010-11-316745","volume":"117","author":"JI Cohen","year":"2011","unstructured":"Cohen JI et al (2011) Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 117(22):5835\u20135849","journal-title":"Blood"},{"issue":"5","key":"336_CR18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10875-015-0168-y","volume":"35","author":"JI Cohen","year":"2015","unstructured":"Cohen JI et al (2015) Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1). J Clin Immunol 35(5):445\u2013448","journal-title":"J Clin Immunol"},{"issue":"4","key":"336_CR19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/10428194.2019.1699080","volume":"61","author":"JI Cohen","year":"2020","unstructured":"Cohen JI et al (2020) Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. Leuk Lymphoma 61(4):808\u2013819","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"336_CR20","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1128\/JVI.03001-14","volume":"89","author":"CB Coleman","year":"2015","unstructured":"Coleman CB et al (2015) Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol 89(4):2301\u20132312","journal-title":"J Virol"},{"key":"336_CR21","doi-asserted-by":"crossref","unstructured":"Coleman CB et al (2018) Epstein-Barr virus type 2 infects T cells and induces B cell lymphomagenesis in humanized mice. J Virol 92(21)","DOI":"10.1128\/JVI.00813-18"},{"issue":"2","key":"336_CR22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood.2020005611","volume":"137","author":"P Collins","year":"2020","unstructured":"Collins P et al (2020) Characterising EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood 137(2):203\u2013215","journal-title":"Blood"},{"issue":"2","key":"336_CR23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood.2020005611","volume":"137","author":"PJ Collins","year":"2021","unstructured":"Collins PJ et al (2021) Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood 137(2):203\u2013215","journal-title":"Blood"},{"key":"336_CR24","doi-asserted-by":"crossref","unstructured":"Cristescu R et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362(6411)","DOI":"10.1126\/science.aar3593"},{"issue":"2","key":"336_CR25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/bloodadvances.2021005291","volume":"6","author":"BJ Davila Saldana","year":"2022","unstructured":"Davila Saldana BJ et al (2022) High risk of relapsed disease in patients with NK\/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv 6(2):452\u2013459","journal-title":"Blood Adv"},{"key":"336_CR26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fped.2018.00405","volume":"6","author":"S de Mel","year":"2018","unstructured":"de Mel S et al (2018) Transcriptomic abnormalities in Epstein Barr virus associated T\/NK lymphoproliferative disorders. Front Pediatr 6:405","journal-title":"Front Pediatr"},{"issue":"3","key":"336_CR27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/eji.200535485","volume":"36","author":"A Demachi-Okamura","year":"2006","unstructured":"Demachi-Okamura A et al (2006) Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. Eur J Immunol 36(3):593\u2013602","journal-title":"Eur J Immunol"},{"issue":"2","key":"336_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2007.06.014","volume":"40","author":"AS Elazary","year":"2007","unstructured":"Elazary AS et al (2007) Severe Epstein-Barr virus-associated hemophagocytic syndrome in six adult patients. J Clin Virol 40(2):156\u2013159","journal-title":"J Clin Virol"},{"issue":"1","key":"336_CR29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.17638","volume":"196","author":"NK El-Mallawany","year":"2022","unstructured":"El-Mallawany NK, Curry CV, Allen CE (2022) Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes. Br J Haematol 196(1):31\u201344","journal-title":"Br J Haematol"},{"key":"336_CR30","unstructured":"England N (2021) Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages"},{"issue":"9","key":"336_CR31","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L et al (2014) Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66(9):2613\u20132620","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"336_CR32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/hon.2758","volume":"38","author":"Y Feng","year":"2020","unstructured":"Feng Y et al (2020) Predicting treatment response of patients with extranodal natural killer\/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1. Hematol Oncol 38(4):467\u2013477","journal-title":"Hematol Oncol"},{"key":"336_CR33","doi-asserted-by":"crossref","unstructured":"Fournier B et al (2020) Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med 217(11)","DOI":"10.1084\/jem.20192262"},{"issue":"19","key":"336_CR34","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1182\/blood-2010-06-292268","volume":"116","author":"CP Fox","year":"2010","unstructured":"Fox CP et al (2010) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116(19):3695\u20133704","journal-title":"Blood"},{"issue":"3","key":"336_CR35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger R et al (2016) L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167(3):829\u2013842 e13","journal-title":"Cell"},{"key":"336_CR36","doi-asserted-by":"crossref","first-page":"1161848","DOI":"10.3389\/fimmu.2023.1161848","volume":"14","author":"A Glover","year":"2023","unstructured":"Glover A, Zhang Z, Shannon-Lowe C (2023) Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis. Front Immunol 14:1161848","journal-title":"Front Immunol"},{"issue":"3","key":"336_CR37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11596-021-2375-5","volume":"41","author":"YQ Guan","year":"2021","unstructured":"Guan YQ et al (2021) Inherited genetic susceptibility to nonimmunosuppressed Epstein-Barr virus-associated T\/NK-cell lymphoproliferative diseases in Chinese patients. Curr Med Sci 41(3):482\u2013490","journal-title":"Curr Med Sci"},{"issue":"4","key":"336_CR38","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T et al (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110(4):1123\u20131131","journal-title":"Blood"},{"issue":"7","key":"336_CR39","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI et al (2002) Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100(7):2367\u20132373","journal-title":"Blood"},{"issue":"7","key":"336_CR40","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/1346-8138.16842","volume":"50","author":"Y Hirai","year":"2023","unstructured":"Hirai Y et al (2023) Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy. J Dermatol 50(7):e198\u2013e205","journal-title":"J Dermatol"},{"issue":"7","key":"336_CR41","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/infdis\/jiaa232","volume":"222","author":"MK Howe","year":"2020","unstructured":"Howe MK et al (2020) Patients with natural killer (NK) cell chronic active Epstein-Barr virus have immature NK cells and hyperactivation of PI3K\/Akt\/mTOR and STAT1 pathways. J Infect Dis 222(7):1170\u20131179","journal-title":"J Infect Dis"},{"issue":"1","key":"336_CR42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X et al (2021) The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 6(1):402","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"336_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/modpathol.3800369","volume":"18","author":"SD Hudnall","year":"2005","unstructured":"Hudnall SD et al (2005) Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol 18(4):519\u2013527","journal-title":"Mod Pathol"},{"issue":"3","key":"336_CR44","doi-asserted-by":"crossref","first-page":"266","DOI":"10.18683\/germs.2020.1216","volume":"10","author":"P Ioannou","year":"2020","unstructured":"Ioannou P et al (2020) Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study. Germs 10(3):266\u2013271","journal-title":"Germs"},{"key":"336_CR45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fped.2019.00183","volume":"7","author":"M Ishimura","year":"2019","unstructured":"Ishimura M et al (2019) Systemic Epstein-Barr virus-positive T\/NK lymphoproliferative diseases with SH2D1A\/XIAP hypomorphic gene variants. Front Pediatr 7:183","journal-title":"Front Pediatr"},{"issue":"3","key":"336_CR46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/jclinpath-2011-200523","volume":"65","author":"Y Isobe","year":"2012","unstructured":"Isobe Y et al (2012) T\/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T\/NK-cell lymphoma. J Clin Pathol 65(3):278\u2013282","journal-title":"J Clin Pathol"},{"issue":"11","key":"336_CR47","doi-asserted-by":"crossref","first-page":"ofad516","DOI":"10.1093\/ofid\/ofad516","volume":"10","author":"J Jin","year":"2023","unstructured":"Jin J et al (2023) EBV-encoded MicroRNA-BART17-3p targets DDX3X and promotes EBV infection in EBV-associated T\/natural killer-cell lymphoproliferative diseases. Open Forum Infect Dis 10(11):ofad516","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"336_CR48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jmv.1890280211","volume":"28","author":"J Joncas","year":"1989","unstructured":"Joncas J et al (1989) Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. J Med Virol 28(2):110\u2013117","journal-title":"J Med Virol"},{"issue":"1","key":"336_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-102-1-","volume":"102","author":"JF Jones","year":"1985","unstructured":"Jones JF et al (1985) Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 102(1):1\u20137","journal-title":"Ann Intern Med"},{"issue":"15","key":"336_CR50","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB et al (2011) How I treat hemophagocytic lymphohistiocytosis. Blood 118(15):4041\u20134052","journal-title":"Blood"},{"issue":"7607","key":"336_CR51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K et al (2016) Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534(7607):402\u2013406","journal-title":"Nature"},{"issue":"7","key":"336_CR52","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","volume":"33","author":"K Kataoka","year":"2019","unstructured":"Kataoka K et al (2019) Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 33(7):1687\u20131699","journal-title":"Leukemia"},{"issue":"5","key":"336_CR53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12185-023-03660-5","volume":"118","author":"JI Kawada","year":"2023","unstructured":"Kawada JI et al (2023) Updated guidelines for chronic active Epstein-Barr virus disease. Int J Hematol 118(5):568\u2013576","journal-title":"Int J Hematol"},{"issue":"6","key":"336_CR54","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3324\/haematol.2017.174177","volume":"103","author":"K Kawamoto","year":"2018","unstructured":"Kawamoto K et al (2018) A distinct subtype of Epstein-Barr virus-positive T\/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Haematologica 103(6):1018\u20131028","journal-title":"Haematologica"},{"issue":"6172","key":"336_CR55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/333455a0","volume":"333","author":"H Kikuta","year":"1988","unstructured":"Kikuta H et al (1988) Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 333(6172):455\u2013457","journal-title":"Nature"},{"key":"336_CR56","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/978-981-10-7230-7_21","volume":"1045","author":"H Kimura","year":"2018","unstructured":"Kimura H (2018) EBV in T-\/NK-cell tumorigenesis. Adv Exp Med Biol 1045:459\u2013475","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"336_CR57","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1086\/367988","volume":"187","author":"H Kimura","year":"2003","unstructured":"Kimura H et al (2003) Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187(4):527\u2013533","journal-title":"J Infect Dis"},{"issue":"4","key":"336_CR58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/427239","volume":"191","author":"H Kimura","year":"2005","unstructured":"Kimura H et al (2005) Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 191(4):531\u2013539","journal-title":"J Infect Dis"},{"issue":"3","key":"336_CR59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2011-10-381921","volume":"119","author":"H Kimura","year":"2012","unstructured":"Kimura H et al (2012) EBV-associated T\/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119(3):673\u2013686","journal-title":"Blood"},{"issue":"7","key":"336_CR60","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1182\/blood-2005-06-2569","volume":"107","author":"LL Kis","year":"2006","unstructured":"Kis LL et al (2006) IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 107(7):2928\u20132935","journal-title":"Blood"},{"issue":"2","key":"336_CR61","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41375-024-02135-8","volume":"38","author":"J Knauft","year":"2024","unstructured":"Knauft J et al (2024) Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38(2):235\u2013249","journal-title":"Leukemia"},{"issue":"22","key":"336_CR62","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1182\/blood-2008-11-190090","volume":"113","author":"H Kohlhof","year":"2009","unstructured":"Kohlhof H et al (2009) Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood 113(22):5506\u20135515","journal-title":"Blood"},{"key":"336_CR63","doi-asserted-by":"crossref","unstructured":"Ku YC et al (2019) DDX3 participates in translational control of inflammation induced by infections and injuries. Mol Cell Biol 39(1)","DOI":"10.1128\/MCB.00285-18"},{"issue":"23","key":"336_CR64","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Rosee","year":"2019","unstructured":"La Rosee P et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465\u20132477","journal-title":"Blood"},{"issue":"1","key":"336_CR65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/febs.13553","volume":"283","author":"MC Lai","year":"2016","unstructured":"Lai MC et al (2016) DDX3 functions in antiviral innate immunity through translational control of PACT. FEBS J 283(1):88\u2013101","journal-title":"FEBS J"},{"issue":"3","key":"336_CR66","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10238-021-00689-w","volume":"21","author":"J Lin","year":"2021","unstructured":"Lin J et al (2021) Clinicopathologic findings of chronic active Epstein-Barr virus infection in adults: a single-center retrospective study in China. Clin Exp Med 21(3):369\u2013377","journal-title":"Clin Exp Med"},{"issue":"4","key":"336_CR67","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00277-016-2911-8","volume":"96","author":"S Liu","year":"2017","unstructured":"Liu S et al (2017) Comprehensive assessment of peripheral blood TCRbeta repertoire in infectious mononucleosis and chronic active EBV infection patients. Ann Hematol 96(4):665\u2013680","journal-title":"Ann Hematol"},{"issue":"19","key":"336_CR68","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F et al (2020) Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med 382(19):1811\u20131822","journal-title":"N Engl J Med"},{"key":"336_CR69","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3389\/fimmu.2019.02193","volume":"10","author":"HM Long","year":"2019","unstructured":"Long HM, Meckiff BJ, Taylor GS (2019) The T-cell response to Epstein-Barr virus-new tricks from an old dog. Front Immunol 10:2193","journal-title":"Front Immunol"},{"issue":"9","key":"336_CR70","volume":"97","author":"L Luo","year":"2018","unstructured":"Luo L et al (2018) The clinical characteristics and the features of immunophenotype of peripheral lymphocytes of adult onset chronic active Epstein-Barr virus disease at a tertiary Care Hospital in Beijing. Medicine (Baltimore) 97(9):e9854","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"336_CR71","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jaci.2022.11.012","volume":"151","author":"H Luo","year":"2023","unstructured":"Luo H et al (2023) Clinical and genetic characterization of Epstein-Barr virus-associated T\/NK-cell lymphoproliferative diseases. J Allergy Clin Immunol 151(4):1096\u20131109","journal-title":"J Allergy Clin Immunol"},{"key":"336_CR72","doi-asserted-by":"crossref","first-page":"1093719","DOI":"10.3389\/fimmu.2023.1093719","volume":"14","author":"Y Ma","year":"2023","unstructured":"Ma Y et al (2023) Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: a single center retrospective analysis. Front Immunol 14:1093719","journal-title":"Front Immunol"},{"issue":"5","key":"336_CR73","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1074-7613(01)00226-6","volume":"15","author":"TE Morrison","year":"2001","unstructured":"Morrison TE et al (2001) Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 15(5):787\u2013799","journal-title":"Immunity"},{"issue":"7","key":"336_CR74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.micinf.2014.04.004","volume":"16","author":"M Murakami","year":"2014","unstructured":"Murakami M et al (2014) PCR array analysis of gene expression profiles in chronic active Epstein-Barr virus infection. Microbes Infect 16(7):581\u2013586","journal-title":"Microbes Infect"},{"issue":"1","key":"336_CR75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","volume":"10","author":"J Nie","year":"2025","unstructured":"Nie J et al (2025) Deep insight into cytokine storm: from pathogenesis to treatment. Signal Transduct Target Ther 10(1):112","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"336_CR76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<26::AID-AJH6>3.0.CO;2-R","volume":"61","author":"S Ohga","year":"1999","unstructured":"Ohga S et al (1999) Restricted diversification of T-cells in chronic active Epstein-Barr virus infection: potential inclination to T-lymphoproliferative disease. Am J Hematol 61(1):26\u201333","journal-title":"Am J Hematol"},{"issue":"1","key":"336_CR77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcv.2011.01.014","volume":"51","author":"S Ohga","year":"2011","unstructured":"Ohga S et al (2011) Clonal origin of Epstein-Barr virus (EBV)-infected T\/NK-cell subpopulations in EBV-positive T\/NK-cell lymphoproliferative disorders of childhood. J Clin Virol 51(1):31\u201337","journal-title":"J Clin Virol"},{"issue":"3","key":"336_CR78","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","volume":"4","author":"Y Okuno","year":"2019","unstructured":"Okuno Y et al (2019) Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4(3):404\u2013413","journal-title":"Nat Microbiol"},{"issue":"57","key":"336_CR79","doi-asserted-by":"crossref","first-page":"31077","DOI":"10.18632\/oncotarget.25780","volume":"9","author":"E Onozawa","year":"2018","unstructured":"Onozawa E et al (2018) STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target. Oncotarget 9(57):31077\u201331089","journal-title":"Oncotarget"},{"issue":"1","key":"336_CR80","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1038\/s41598-025-90766-x","volume":"15","author":"J Oppenauer","year":"2025","unstructured":"Oppenauer J et al (2025) Secondary Hemophagocytic Lymphohistiocytosis in severe COVID-19 \u2013 a retrospective cohort study. Sci Rep 15(1):6137","journal-title":"Sci Rep"},{"issue":"3","key":"336_CR81","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.23911","volume":"90","author":"ZK Otrock","year":"2015","unstructured":"Otrock ZK, Eby CS (2015) Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 90(3):220\u2013224","journal-title":"Am J Hematol"},{"issue":"1","key":"336_CR82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10428194.2016.1179297","volume":"58","author":"JH Paik","year":"2017","unstructured":"Paik JH et al (2017) Clinicopathological categorization of Epstein-Barr virus-positive T\/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Leuk Lymphoma 58(1):53\u201363","journal-title":"Leuk Lymphoma"},{"key":"336_CR83","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/nyas.12937","volume":"1356","author":"U Palendira","year":"2015","unstructured":"Palendira U, Rickinson AB (2015) Primary immunodeficiencies and the control of Epstein-Barr virus infection. Ann N Y Acad Sci 1356:22\u201344","journal-title":"Ann N Y Acad Sci"},{"key":"336_CR84","doi-asserted-by":"crossref","unstructured":"Pekalski ML et al (2017) Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. JCI. Insight 2(16)","DOI":"10.1172\/jci.insight.93739"},{"issue":"6","key":"336_CR85","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41375-018-0324-5","volume":"33","author":"RJ Peng","year":"2019","unstructured":"Peng RJ et al (2019) Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. Leukemia 33(6):1451\u20131462","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"336_CR86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2399","volume":"35","author":"L Quintanilla-Martinez","year":"2017","unstructured":"Quintanilla-Martinez L (2017) The 2016 updated WHO classification of lymphoid neoplasias. Hematol Oncol 35(Suppl 1):37\u201345","journal-title":"Hematol Oncol"},{"issue":"9927","key":"336_CR87","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M et al (2014) Adult haemophagocytic syndrome. Lancet 383(9927):1503\u20131516","journal-title":"Lancet"},{"issue":"4","key":"336_CR88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.it.2014.01.003","volume":"35","author":"AB Rickinson","year":"2014","unstructured":"Rickinson AB et al (2014) Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol 35(4):159\u2013169","journal-title":"Trends Immunol"},{"issue":"12","key":"336_CR89","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1084\/jem.20190678","volume":"216","author":"R Rodriguez","year":"2019","unstructured":"Rodriguez R et al (2019) Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J Exp Med 216(12):2800\u20132818","journal-title":"J Exp Med"},{"key":"336_CR90","doi-asserted-by":"crossref","unstructured":"Samir P, Kanneganti TD (2022) DEAD\/H-box helicases in immunity, inflammation, cell differentiation, and cell death and disease. Cells 11(10)","DOI":"10.3390\/cells11101608"},{"issue":"12","key":"336_CR91","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2002-01-0039","volume":"100","author":"B Savoldo","year":"2002","unstructured":"Savoldo B et al (2002) Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 100(12):4059\u20134066","journal-title":"Blood"},{"issue":"9","key":"336_CR92","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","volume":"108","author":"B Savoldo","year":"2006","unstructured":"Savoldo B et al (2006) Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108(9):2942\u20132949","journal-title":"Blood"},{"issue":"19","key":"336_CR93","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","volume":"125","author":"AM Schram","year":"2015","unstructured":"Schram AM, Berliner N (2015) How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125(19):2908\u20132914","journal-title":"Blood"},{"issue":"19","key":"336_CR94","first-page":"4775","volume":"4","author":"N Sejic","year":"2020","unstructured":"Sejic N et al (2020) BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T\/NK-cell lymphoma. Blood Adv 4(19):4775\u20134787","journal-title":"Blood Adv"},{"key":"336_CR95","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A (2019) The global landscape of EBV-associated tumors. Front Oncol 9:713","journal-title":"Front Oncol"},{"issue":"4","key":"336_CR96","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/10428194.2016.1213823","volume":"58","author":"A Shatzer","year":"2017","unstructured":"Shatzer A et al (2017) Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood. Leuk Lymphoma 58(4):923\u2013931","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"336_CR97","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song TL et al (2018) Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood 132(11):1146\u20131158","journal-title":"Blood"},{"key":"336_CR98","volume":"12","author":"Y Song","year":"2021","unstructured":"Song Y et al (2021) Ruxolitinib in patients with chronic active Epstein-Barr virus infection: a retrospective, single-center study. Front Pharmacol 12:710400","journal-title":"Front Pharmacol"},{"issue":"6","key":"336_CR99","doi-asserted-by":"crossref","first-page":"796 e7","DOI":"10.1016\/j.cmi.2023.01.017","volume":"29","author":"Y Song","year":"2023","unstructured":"Song Y et al (2023) PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection. Clin Microbiol Infect 29(6):796 e7\u2013796 e13","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"336_CR100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1086\/423285","volume":"190","author":"N Sugaya","year":"2004","unstructured":"Sugaya N et al (2004) Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. J Infect Dis 190(5):985\u2013988","journal-title":"J Infect Dis"},{"key":"336_CR101","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon"},{"key":"336_CR102","unstructured":"Swerdlow SH, Campo E., Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds) WHO classification of tumours, Revised 4th edition. IARC Publications"},{"issue":"12","key":"336_CR103","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/ijc.22139","volume":"119","author":"M Takahara","year":"2006","unstructured":"Takahara M et al (2006) Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 119(12):2775\u20132783","journal-title":"Int J Cancer"},{"key":"336_CR104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor GS et al (2015) The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 33:787\u2013821","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"336_CR105","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/eji.1830180823","volume":"18","author":"CD Tsoukas","year":"1988","unstructured":"Tsoukas CD, Lambris JD (1988) Expression of CR2\/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol 18(8):1299\u20131302","journal-title":"Eur J Immunol"},{"issue":"2","key":"336_CR106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/jmv.1029","volume":"64","author":"I Tsuge","year":"2001","unstructured":"Tsuge I et al (2001) Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol 64(2):141\u2013148","journal-title":"J Med Virol"},{"issue":"1","key":"336_CR107","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100053","volume":"2","author":"Y Uemura","year":"2025","unstructured":"Uemura Y et al (2025) JAK1\/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. Blood Neoplasia 2(1):100053","journal-title":"Blood Neoplasia"},{"issue":"1","key":"336_CR108","first-page":"62","volume":"38","author":"L Wang","year":"2018","unstructured":"Wang L et al (2018) IL-2Ralpha up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer\/T-cell lymphoma. Cancer Commun (Lond) 38(1):62","journal-title":"Cancer Commun (Lond)"},{"issue":"39","key":"336_CR109","volume":"103","author":"W Wang","year":"2024","unstructured":"Wang W et al (2024) Emapalumab as a therapeutic intervention for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: a case series. Medicine (Baltimore) 103(39):e39880","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"336_CR110","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.173.4.971","volume":"173","author":"D Watry","year":"1991","unstructured":"Watry D et al (1991) Infection of human thymocytes by Epstein-Barr virus. J Exp Med 173(4):971\u2013980","journal-title":"J Exp Med"},{"issue":"12","key":"336_CR111","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00394-22","volume":"96","author":"W Wongwiwat","year":"2022","unstructured":"Wongwiwat W et al (2022) Epstein-Barr virus genome deletions in Epstein-Barr virus-positive T\/NK cell lymphoproliferative diseases. J Virol 96(12):e0039422","journal-title":"J Virol"},{"issue":"4","key":"336_CR112","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/1547691X.2012.758199","volume":"10","author":"Y Xing","year":"2013","unstructured":"Xing Y et al (2013) Clinical significance of variations in levels of Epstein-Barr virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children. J Immunotoxicol 10(4):387\u2013392","journal-title":"J Immunotoxicol"},{"key":"336_CR113","doi-asserted-by":"crossref","first-page":"1451977","DOI":"10.3389\/fimmu.2024.1451977","volume":"15","author":"S Yan","year":"2024","unstructured":"Yan S et al (2024) Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease. Front Immunol 15:1451977","journal-title":"Front Immunol"},{"issue":"13","key":"336_CR114","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/bloodadvances.2020001451","volume":"4","author":"I Yonese","year":"2020","unstructured":"Yonese I et al (2020) Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv 4(13):2918\u20132926","journal-title":"Blood Adv"},{"issue":"11","key":"336_CR115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112564","volume":"9","author":"M Yoshimori","year":"2014","unstructured":"Yoshimori M et al (2014) CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PLoS One 9(11):e112564","journal-title":"PLoS One"},{"issue":"12","key":"336_CR116","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00262-015-1765-6","volume":"64","author":"H Zhang","year":"2015","unstructured":"Zhang H et al (2015) Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK\/T cell lymphoma: a novel prognostic indicator. Cancer Immunol Immunother 64(12):1587\u20131599","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"336_CR117","doi-asserted-by":"crossref","first-page":"17775","DOI":"10.1038\/s41598-017-18195-z","volume":"7","author":"H Zhong","year":"2017","unstructured":"Zhong H et al (2017) Whole transcriptome profiling reveals major cell types in the cellular immune response against acute and chronic active Epstein-Barr virus infection. Sci Rep 7(1):17775","journal-title":"Sci Rep"}],"container-title":["Current Topics in Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2025_336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:12:19Z","timestamp":1764666739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2025_336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":117,"URL":"https:\/\/doi.org\/10.1007\/82_2025_336","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"3 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}